ID   PNMT_HUMAN              Reviewed;         282 AA.
AC   P11086;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   31-MAY-2011, entry version 115.
DE   RecName: Full=Phenylethanolamine N-methyltransferase;
DE            Short=PNMTase;
DE            EC=2.1.1.28;
DE   AltName: Full=Noradrenaline N-methyltransferase;
GN   Name=PNMT; Synonyms=PENT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=88227966; PubMed=3372503;
RA   Kaneda N., Ichinose H., Kobayashi K., Oka K., Kishi F., Nakazawa A.,
RA   Kurosawa Y., Fujita K., Nagatsu T.;
RT   "Molecular cloning of cDNA and chromosomal assignment of the gene for
RT   human phenylethanolamine N-methyltransferase, the enzyme for
RT   epinephrine biosynthesis.";
RL   J. Biol. Chem. 263:7672-7677(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RA   Sasaoka T., Kaneda N., Kurosawa Y., Fujita K., Nagatsu T.;
RT   "Structure of human phenylethanolamine N-methyltransferase gene:
RT   existence of two types of mRNA with different transcription initiation
RT   sites.";
RL   Neurochem. Int. 15:555-565(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=88217959; PubMed=2835776; DOI=10.1073/pnas.85.10.3648;
RA   Baetge E.E., Behringer R.R., Messing A., Brinster R.L., Palmiter R.D.;
RT   "Transgenic mice express the human phenylethanolamine N-
RT   methyltransferase gene in adrenal medulla and retina.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:3648-3652(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, Lung, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH
RP   S-ADENOSYL-L-HOMOCYSTEINE AND SYNTHETIC INHIBITOR.
RX   PubMed=11591352; DOI=10.1016/S0969-2126(01)00662-1;
RA   Martin J.L., Begun J., McLeish M.J., Caine J.M., Grunewald G.L.;
RT   "Getting the adrenaline going: crystal structure of the adrenaline-
RT   synthesizing enzyme PNMT.";
RL   Structure 9:977-985(2001).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) IN COMPLEXES WITH SUBSTRATE
RP   ANALOGS AND S-ADENOSYL-L-HOMOCYSTEINE, BIOPHYSICOCHEMICAL PROPERTIES,
RP   AND MUTAGENESIS OF TYR-35; GLU-185; GLU-219 AND ASP-267.
RX   PubMed=16363801; DOI=10.1021/bi051636b;
RA   Gee C.L., Tyndall J.D.A., Grunewald G.L., Wu Q., McLeish M.J.,
RA   Martin J.L.;
RT   "Mode of binding of methyl acceptor substrates to the adrenaline-
RT   synthesizing enzyme phenylethanolamine N-methyltransferase:
RT   implications for catalysis.";
RL   Biochemistry 44:16875-16885(2005).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) IN COMPLEX WITH SYNTHETIC
RP   INHIBITOR.
RX   PubMed=16942016; DOI=10.1021/jm060466d;
RA   Grunewald G.L., Seim M.R., Regier R.C., Martin J.L., Gee C.L.,
RA   Drinkwater N., Criscione K.R.;
RT   "Comparison of the binding of 3-fluoromethyl-7-sulfonyl-1,2,3,4-
RT   tetrahydroisoquinolines with their isosteric sulfonamides to the
RT   active site of phenylethanolamine N-methyltransferase.";
RL   J. Med. Chem. 49:5424-5433(2006).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) IN COMPLEXES WITH SYNTHETIC
RP   INHIBITOR.
RX   PubMed=17845018; DOI=10.1021/jm0703385;
RA   Gee C.L., Drinkwater N., Tyndall J.D.A., Grunewald G.L., Wu Q.,
RA   McLeish M.J., Martin J.L.;
RT   "Enzyme adaptation to inhibitor binding: a cryptic binding site in
RT   phenylethanolamine N-methyltransferase.";
RL   J. Med. Chem. 50:4845-4853(2007).
RN   [9]
RP   VARIANTS SER-9; ALA-98; CYS-112 AND THR-175, AND CHARACTERIZATION OF
RP   VARIANT ALA-98.
RX   PubMed=16277617; DOI=10.1111/j.1471-4159.2005.03453.x;
RA   Ji Y., Salavaggione O.E., Wang L., Adjei A.A., Eckloff B.,
RA   Wieben E.D., Weinshilboum R.M.;
RT   "Human phenylethanolamine N-methyltransferase pharmacogenomics: gene
RT   re-sequencing and functional genomics.";
RL   J. Neurochem. 95:1766-1776(2005).
CC   -!- FUNCTION: Converts noradrenaline to adrenaline.
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + phenylethanolamine =
CC       S-adenosyl-L-homocysteine + N-methylphenylethanolamine.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=99 uM for phenylethanolamine;
CC         KM=3.4 uM for S-adenosyl-L-methionine;
CC   -!- PATHWAY: Catecholamine biosynthesis; (R)-adrenaline biosynthesis;
CC       (R)-adrenaline from (R)-noradrenaline: step 1/1.
CC   -!- SIMILARITY: Belongs to the NNMT/PNMT/TEMT family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J03727; AAA60130.1; -; mRNA.
DR   EMBL; X52730; CAA36944.1; -; Genomic_DNA.
DR   EMBL; J03280; AAA60131.1; -; Genomic_DNA.
DR   EMBL; BC037246; AAH37246.1; -; mRNA.
DR   IPI; IPI00003466; -.
DR   PIR; A28171; A28171.
DR   RefSeq; NP_002677.1; NM_002686.3.
DR   UniGene; Hs.1892; -.
DR   PDB; 1HNN; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 1N7I; X-ray; 2.80 A; A/B=1-282.
DR   PDB; 1N7J; X-ray; 2.70 A; A/B=1-282.
DR   PDB; 1YZ3; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 2AN3; X-ray; 2.20 A; A/B=1-282.
DR   PDB; 2AN4; X-ray; 2.20 A; A/B=1-282.
DR   PDB; 2AN5; X-ray; 2.50 A; A/B=1-282.
DR   PDB; 2G70; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 2G71; X-ray; 2.20 A; A/B=1-282.
DR   PDB; 2G72; X-ray; 2.00 A; A/B=1-282.
DR   PDB; 2G8N; X-ray; 2.15 A; A/B=1-282.
DR   PDB; 2OBF; X-ray; 2.30 A; A/B=1-282.
DR   PDB; 2ONY; X-ray; 2.60 A; A/B=1-282.
DR   PDB; 2ONZ; X-ray; 2.80 A; A/B=1-282.
DR   PDB; 2OPB; X-ray; 2.80 A; A/B=1-282.
DR   PDB; 3HCA; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3HCB; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3HCC; X-ray; 2.30 A; A/B=1-282.
DR   PDB; 3HCD; X-ray; 2.39 A; A/B=1-282.
DR   PDB; 3HCE; X-ray; 2.85 A; A/B=1-282.
DR   PDB; 3HCF; X-ray; 2.70 A; A/B=1-282.
DR   PDB; 3KPJ; X-ray; 2.50 A; A/B=1-282.
DR   PDB; 3KPU; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KPV; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KPW; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KPY; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KQM; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KQO; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KQP; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KQQ; X-ray; 2.50 A; A/B=1-282.
DR   PDB; 3KQS; X-ray; 2.00 A; A/B=1-282.
DR   PDB; 3KQT; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KQV; X-ray; 2.30 A; A/B=1-282.
DR   PDB; 3KQW; X-ray; 2.49 A; A/B=1-282.
DR   PDB; 3KQY; X-ray; 2.20 A; A/B=1-282.
DR   PDB; 3KR0; X-ray; 2.60 A; A/B=1-282.
DR   PDB; 3KR1; X-ray; 2.30 A; A/B=1-282.
DR   PDB; 3KR2; X-ray; 2.30 A; A/B=1-282.
DR   PDBsum; 1HNN; -.
DR   PDBsum; 1N7I; -.
DR   PDBsum; 1N7J; -.
DR   PDBsum; 1YZ3; -.
DR   PDBsum; 2AN3; -.
DR   PDBsum; 2AN4; -.
DR   PDBsum; 2AN5; -.
DR   PDBsum; 2G70; -.
DR   PDBsum; 2G71; -.
DR   PDBsum; 2G72; -.
DR   PDBsum; 2G8N; -.
DR   PDBsum; 2OBF; -.
DR   PDBsum; 2ONY; -.
DR   PDBsum; 2ONZ; -.
DR   PDBsum; 2OPB; -.
DR   PDBsum; 3HCA; -.
DR   PDBsum; 3HCB; -.
DR   PDBsum; 3HCC; -.
DR   PDBsum; 3HCD; -.
DR   PDBsum; 3HCE; -.
DR   PDBsum; 3HCF; -.
DR   PDBsum; 3KPJ; -.
DR   PDBsum; 3KPU; -.
DR   PDBsum; 3KPV; -.
DR   PDBsum; 3KPW; -.
DR   PDBsum; 3KPY; -.
DR   PDBsum; 3KQM; -.
DR   PDBsum; 3KQO; -.
DR   PDBsum; 3KQP; -.
DR   PDBsum; 3KQQ; -.
DR   PDBsum; 3KQS; -.
DR   PDBsum; 3KQT; -.
DR   PDBsum; 3KQV; -.
DR   PDBsum; 3KQW; -.
DR   PDBsum; 3KQY; -.
DR   PDBsum; 3KR0; -.
DR   PDBsum; 3KR1; -.
DR   PDBsum; 3KR2; -.
DR   ProteinModelPortal; P11086; -.
DR   SMR; P11086; 14-281.
DR   STRING; P11086; -.
DR   PRIDE; P11086; -.
DR   Ensembl; ENST00000269582; ENSP00000269582; ENSG00000141744.
DR   GeneID; 5409; -.
DR   KEGG; hsa:5409; -.
DR   UCSC; uc002hsi.1; human.
DR   CTD; 5409; -.
DR   GeneCards; GC17P033618; -.
DR   H-InvDB; HIX0027187; -.
DR   HGNC; HGNC:9160; PNMT.
DR   HPA; CAB017029; -.
DR   MIM; 171190; gene.
DR   neXtProt; NX_P11086; -.
DR   PharmGKB; PA274; -.
DR   eggNOG; prNOG16585; -.
DR   HOGENOM; HBG270140; -.
DR   HOVERGEN; HBG000797; -.
DR   InParanoid; P11086; -.
DR   OMA; ALEESWY; -.
DR   PhylomeDB; P11086; -.
DR   BioCyc; MetaCyc:ENSG00000141744-MONOMER; -.
DR   Reactome; REACT_13; Metabolism of amino acids and derivatives.
DR   Reactome; REACT_15314; Hormone biosynthesis.
DR   NextBio; 20943; -.
DR   ArrayExpress; P11086; -.
DR   Bgee; P11086; -.
DR   CleanEx; HS_PNMT; -.
DR   Genevestigator; P11086; -.
DR   GermOnline; ENSG00000141744; Homo sapiens.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0004603; F:phenylethanolamine N-methyltransferase activity; EXP:Reactome.
DR   GO; GO:0042423; P:catecholamine biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0042446; P:hormone biosynthetic process; TAS:Reactome.
DR   InterPro; IPR000940; NNMT_TEMT_trans.
DR   PANTHER; PTHR10867; NNMT_TEMT_trans; 1.
DR   Pfam; PF01234; NNMT_PNMT_TEMT; 1.
DR   PIRSF; PIRSF000384; PNMTase; 1.
DR   PROSITE; PS01100; NNMT_PNMT_TEMT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Catecholamine biosynthesis; Complete proteome;
KW   Methyltransferase; Polymorphism; S-adenosyl-L-methionine; Transferase.
FT   CHAIN         1    282       Phenylethanolamine N-methyltransferase.
FT                                /FTId=PRO_0000159709.
FT   REGION       79     80       S-adenosyl-L-methionine binding.
FT   REGION      158    159       S-adenosyl-L-methionine binding.
FT   BINDING      35     35       S-adenosyl-L-methionine.
FT   BINDING      40     40       S-adenosyl-L-methionine.
FT   BINDING      85     85       S-adenosyl-L-methionine.
FT   BINDING     101    101       S-adenosyl-L-methionine.
FT   BINDING     106    106       S-adenosyl-L-methionine.
FT   BINDING     181    181       S-adenosyl-L-methionine; via carbonyl
FT                                oxygen.
FT   BINDING     219    219       Substrate.
FT   VARIANT       9      9       N -> S (in dbSNP:rs11569781).
FT                                /FTId=VAR_029351.
FT   VARIANT      98     98       T -> A (lower activity levels than wild-
FT                                type; dbSNP:rs36060376).
FT                                /FTId=VAR_036829.
FT   VARIANT     112    112       R -> C (in dbSNP:rs34530498).
FT                                /FTId=VAR_036830.
FT   VARIANT     175    175       A -> T (in dbSNP:rs34341496).
FT                                /FTId=VAR_036831.
FT   VARIANT     188    188       S -> C (in dbSNP:rs5639).
FT                                /FTId=VAR_037611.
FT   VARIANT     211    211       L -> H (in dbSNP:rs5640).
FT                                /FTId=VAR_037612.
FT   VARIANT     217    217       L -> Q (in dbSNP:rs5641).
FT                                /FTId=VAR_037613.
FT   VARIANT     254    254       R -> H (in dbSNP:rs5642).
FT                                /FTId=VAR_037614.
FT   VARIANT     276    276       W -> R (in dbSNP:rs5643).
FT                                /FTId=VAR_024547.
FT   MUTAGEN      35     35       Y->F: Strongly increases KM for substrate
FT                                and S-adenosyl-L-methionine.
FT   MUTAGEN     185    185       E->A,Q: Strongly reduced enzyme activity.
FT                                Increases affinity for S-adenosyl-L-
FT                                methionine.
FT   MUTAGEN     185    185       E->D: Strongly reduced enzyme activity.
FT                                Decreases affinity for substrate and S-
FT                                adenosyl-L-methionine 3-fold.
FT   MUTAGEN     219    219       E->A: Reduced enzyme activity. Decreases
FT                                affinity for substrate 6-fold. Decreases
FT                                affinity for S-adenosyl-L-methionine 2-
FT                                fold.
FT   MUTAGEN     267    267       D->A,N: Strongly reduced enzyme activity.
FT                                Decreases affinity for substrate 200-
FT                                fold. Decreases affinity for S-adenosyl-
FT                                L-methionine 3-fold.
FT   CONFLICT    169    170       SP -> AQ (in Ref. 3; AAA60131).
FT   HELIX        17     21
FT   HELIX        23     27
FT   HELIX        32     40
FT   TURN         42     45
FT   HELIX        53     66
FT   STRAND       73     79
FT   HELIX        85     87
FT   TURN         88     90
FT   HELIX        91     93
FT   STRAND       95    100
FT   HELIX       104    114
FT   HELIX       124    134
FT   HELIX       140    150
FT   STRAND      151    155
FT   STRAND      161    163
FT   STRAND      173    182
FT   HELIX       184    187
FT   HELIX       191    202
FT   STRAND      205    218
FT   STRAND      221    225
FT   STRAND      227    230
FT   HELIX       236    245
FT   STRAND      248    257
FT   HELIX       260    262
FT   STRAND      271    279
SQ   SEQUENCE   282 AA;  30855 MW;  56F3A9981D9ABF4C CRC64;
     MSGADRSPNA GAAPDSAPGQ AAVASAYQRF EPRAYLRNNY APPRGDLCNP NGVGPWKLRC
     LAQTFATGEV SGRTLIDIGS GPTVYQLLSA CSHFEDITMT DFLEVNRQEL GRWLQEEPGA
     FNWSMYSQHA CLIEGKGECW QDKERQLRAR VKRVLPIDVH QPQPLGAGSP APLPADALVS
     AFCLEAVSPD LASFQRALDH ITTLLRPGGH LLLIGALEES WYLAGEARLT VVPVSEEEVR
     EALVRSGYKV RDLRTYIMPA HLQTGVDDVK GVFFAWAQKV GL
//
